130 related articles for article (PubMed ID: 31289676)
1. Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.
Yamasaki M; Kimura R; Mayahara S; Maeda Y; Takahashi M; Nishida T; Oda K; Murakami T
Mol Clin Oncol; 2019 Jul; 11(1):43-49. PubMed ID: 31289676
[TBL] [Abstract][Full Text] [Related]
2. Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells.
Yamasaki M; Oda K; Ichinose T; Mizuguchi M; Tominaga S; Omoda K; Mori N; Maeda Y; Nishida T; Murakami T
Oncol Lett; 2022 Nov; 24(5):386. PubMed ID: 36238357
[TBL] [Abstract][Full Text] [Related]
3. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T; Kyomori C; Mizukami T; Taniyama T; Izawa N; Horie Y; Hirakawa M; Ogura T; Nakajima TE; Tsugawa K; Boku N
Mol Clin Oncol; 2016 Apr; 4(4):603-606. PubMed ID: 27073673
[TBL] [Abstract][Full Text] [Related]
4. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients.
Sato Y; Kondo M; Inagaki A; Komatsu H; Okada C; Naruse K; Sahashi T; Kuroda J; Ogura H; Uegaki S; Yoshida T; Mori Y; Sawada H; Watanabe S; Sugiura H; Endo Y; Yoshimoto N; Toyama T; Iida S; Yamada K; Kimura K; Wakita A
J Cancer; 2014; 5(5):390-7. PubMed ID: 24799957
[TBL] [Abstract][Full Text] [Related]
5. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Boccia R; Geller RB; Clendeninn N; Ottoboni T
Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
8. Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.
Sugimoto M; Matsui M; Harada M; Yamauchi Y; Moriyama N; Andou K; Yamamoto M; Yamaoka H; Ono C; Ishikawa M; Kamo N; Ikeda T; Yamaoka K
Gan To Kagaku Ryoho; 2009 Jun; 36(6):969-74. PubMed ID: 19542717
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men.
Azuma J; Fukase H
Clin Pharmacol Drug Dev; 2013 Oct; 2(4):394-9. PubMed ID: 27121944
[TBL] [Abstract][Full Text] [Related]
10. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q
Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181
[TBL] [Abstract][Full Text] [Related]
11. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
[TBL] [Abstract][Full Text] [Related]
12. [Promising new injection method to prevent angialgia/phlebitis from epirubicin hydrochloride therapy for breast cancer].
Ono C; Yamagami M; Kamatani R; Yamamoto M; Mukouyama T; Sugimoto M; Suzuki T; Kamo N; Seki N; Eguchi K; Ikeda T
Gan To Kagaku Ryoho; 2012 May; 39(5):777-81. PubMed ID: 22584330
[TBL] [Abstract][Full Text] [Related]
13. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
14. Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations.
Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
Drug Deliv; 2016 Oct; 23(8):2990-2997. PubMed ID: 26800371
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
17. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
[TBL] [Abstract][Full Text] [Related]
18. [Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer].
Kameda K; Kiba T; Ogawa Y; Kimoto S; Kajiume S; Okada Y; Morii N; Takahashi H; Ichiba Y; Yamashiro H
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1255-7. PubMed ID: 25335710
[TBL] [Abstract][Full Text] [Related]
19. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
